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Abstract 
PURPOSE: Retinitis pigmentosa (RP) is a heterogeneous group of inherited 
conditions that lead to blindness and for which there is no effective therapy. 
Apoptosis of photoreceptors is a common feature in animal models of the 
disease. Thus, we have studied the therapeutic potential of proinsulin, an anti-
apoptotic molecule that is active during retinal development. METHODS: 
Transgenic mice expressing human proinsulin (hPi) in the skeletal muscle were 
generated in a mixed C57BL/6:SJL background and back-crossed to a C57BL/6 
background. Two independent lineages of transgenic mice were established, in 
which hPi production in muscle was constitutive and not regulated by glucose 
levels. hPi levels in serum, muscle and retina were determined with a commercial 
ELISA kit, visual function was evaluated by electroretinogram (ERG) recording 
and programmed cell death was assessed by TUNEL. Immunohistochemistry 
was used to evaluate retinal structure preservation and oxidative damage. 
RESULTS: Transgenic expression of hPi in the rd10 retinal degeneration mouse 
model led to prolonged vision, as determined by ERG recording, in a manner that 
was related to the level of transgene expression. This attenuation of visual 
deterioration was correlated with a delay in photoreceptor apoptosis, as well as 
with the preservation of retinal cytoarchitecture, particularly that of the cones. 
CONCLUSIONS: Our results provide a new basis for possible therapies to 
counteract retinitis pigmentosa, as well as a new tool to dissect out the 
mechanisms involved in the progress of retinal neurodegeneration. 
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Introduction 
Programmed cell death is a self-destructive physiological process essential for 
both, the correct development of an organism and its homeostasis 1. 
Consequently, unregulated cell death underlies many diseases, including 
neurodegenerative disorders 2. Thus, understanding how cell death is regulated 
during neural development may help to establish new therapeutic approaches to 
prevent neurodegeneration 3. 
RP constitutes a large, heterogeneous group of inherited retinal 
neurodegenerative conditions that involve progressive loss of retinal function in 
parallel with the loss of photoreceptors through apoptosis 4-6. Thus, attenuation of 
apoptosis represents good therapeutic target in RP, especially considering the 
vast heterogeneity of the disease 7. The most extensively studied animal model 
of RP is the rd1 mouse, which carries a recessive nonsense mutation in the 
pde6b gene. Indeed, a number of mutations have been found in the catalytic 
domain of the human pde6b gene in patients suffering from autosomal recessive 
RP 8, 9. The rd1 mouse is characterized by an early onset of photoreceptor loss, 
apoptosis peaking around postnatal day (P) 14-15 4, 10. As a consequence, ERG 
recordings of visual function never reach notable values, even in those cases 
where attenuation has been reported. A more recently characterized animal 
model, the rd10 mouse, also carries a recessive mutation in the pde6b gene, 
which produces a delayed phenotype when compared to the rd1 mouse. 
Therefore, ERGs can be readily obtained prior to degeneration in this model 11, 12 
 4
and, accordingly, this situation better resembles the course of the human 
disease. 
Molecules that promote survival, such as growth factors BDNF, CNTF, FGFs, 
GDNF, PEDF, are moderately successful in preventing disease progression 
when employed in animal models 13-18. Antioxidants also provide modest 
protection, probably by reducing the oxidative damage found in the rd1 mouse 
retinas 19, 20. Members of the insulin family are well-characterized neuroprotective 
molecules active both in development and aging 21-23. We have previously 
reported that locally expressed proinsulin acts as survival factor during 
embryonic retinal development in the chick and the mouse 24-27. In the present 
study we show that transgenic human proinsulin expression in rd10 mice 
attenuates retinal degeneration, as assessed by the maintenance of ERG and 
the histological preservation of photoreceptors. Systemic proinsulin was able to 
reach retinal tissue, delay apoptotic death of photoreceptors, and decrease 
oxidative damage. Thus, proinsulin represents a possible new therapy for RP, as 
well as a new tool to dissect out the mechanisms involved in pathological cell 
death. 
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Materials and Methods  
Animals 
All procedures were approved by the respective local ethics committee for animal 
experimentation, and experiments were carried out in accordance with the 
European Union guidelines and ARVO statement for use of animals in 
ophthalmic and vision research. Control wild type (wt) C57BL/6J mice were 
obtained from the Jackson Laboratory (Bar Harbor, ME). The mouse model of 
retinal degeneration, pde6brd10 (rd10), also on a C57BL/6J background, was 
kindly provided by Dr. B. Chang (Jackson Laboratory).  
Transgenic mice expressing human proinsulin (hPI) driven by the myosin light 
chain (MCL)-I promoter and a muscle-specific enhancer were generated on a 
mixed C57BL/6:SJL background and back-crossed to a C57BL/6 background. 
Two lines of transgenic mice (L1 and L2) were established in which hPi 
production in muscle was constitutive and not regulated by glucose levels. 
Expression of hPi in transgenic mice was confirmed by ELISA of muscle and 
serum samples, whereas hPi was undetectable in non-transgenic animals. 
Glucose levels in serum, as well as weight of transgenic mice in comparison with 
wt animals were followed over a period of 13 months (Supplementary Fig. 1). 
The rd10 mice used in this study were homozygous for the pde6brd10 mutation, 
while the transgenic mice were either homozygous or hemizygous for the hPi 
transgene, as indicated.  
The hPi genotype was determined by Southern blotting using specific dCT32P 
labeled probes for hPi and for mouse S16 as a reference gene (Random Primer 
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Kit, Stratagene, La Jolla, CA), hybridized at the same time. Phosphorimager IP 
software (Fuji Film, Kanagawa, Japan) was used to quantify the signal 
corresponding to the respective specific bands, and the ratio between both bands 
was used to establish the zygosity of each transgenic animal.  
The rd10 genotypes were assessed as recommended by the Jackson Laboratory  
11.  
ERG recordings 
Mice were dark-adapted overnight and subsequent manipulations and ERG 
recordings were performed in dim red light. Mice were anaesthetized with an 
intraperitoneal injection of a ketamine (95 mg/Kg) and xylazine (5 mg/Kg) 
solution and maintained on a heating pad at 37°C. Pupils were dilated by 
applying a topical drop of 1% tropicamide (Colircusí Tropicamida, Alcon Cusí, El 
Masnou, Barcelona, Spain). To optimize electrical recording, a topical drop of 2% 
Methocel (Ciba Vision, Hetlingen, Switzerland) was instilled on each eye 
immediately before situating the corneal electrode. Flash-induced ERG 
responses were recorded from the right eye in response to light stimuli produced 
with a Ganzfeld stimulator. The intensity of the light stimuli was measured with a 
photometer at the level of the eye (Mavo Monitor USB, Gossen, Nürenberg, 
Germany). At each light intensity, 4–64 consecutive stimuli were averaged with 
an interval between light flashes in scotopic conditions of 10 s for dim flashes 
and of up to 60 s for the highest intensity. In contrast, under photopic conditions 
the interval between light flashes was fixed at 1 s. The ERG signals were 
amplified and band filtered between 0.3 and 1000 Hz with a Grass amplifier 
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(CP511 AC amplifier, Grass Instruments, Quincy, MA). Electrical signals were 
digitized at 20 kHz with a Power Lab data acquisition board (AD Instruments, 
Chalgrove, UK). Bipolar recording was performed between an electrode fixed on 
a corneal lens (Burian-Allen electrode, Hansen Ophthalmic Development Lab, 
Coralville, IA) and a reference electrode located in the mouth, with a ground 
electrode located in the tail. Under dark adaptation, rod-mediated responses 
were recorded to light flashes ranging from -4 to -1.5 log cd·s·m-2, while mixed 
rod- and cone-mediated responses were recorded in response to light flashes 
ranging from -1.5 to 1.5 log cd·s·m-2. Oscillatory potentials (OP) were isolated 
using white flashes of 0.48 log cd·s·m-2 in a recording frequency range of 100–
10000 Hz., and cone-mediated responses to light flashes ranging from 0.5 to 2 
log cd·s·m-2 on a rod-saturating background of 30 cd·m-2 were recorded. Flicker 
responses (20 Hz) to light flashes of 1.5 log cd·s·m-2 were also recorded on a 
rod-saturating background. The amplitudes of the a-wave and b-wave were 
measured off-line and the results averaged. Measurements were performed by 
an observer blind to the experimental condition of the animal.  
Detection of transgenic proinsulin  
Human proinsulin production in transgenic mice was determined both in serum 
and muscle using an ELISA kit (human total proinsulin ELISA kit, LINCO 
Research, St. Louis, MO) according to manufacturer’s instructions. For serum 
determination, 20 µl of serum were assayed in duplicates. For muscle 
determination, quadriceps muscle were first dissected and homogenized in 50 
mM Tris-HCl, pH 7.4, 100 mM NaCl, 0.1% (w/v) Triton X-100 buffer. Duplicates 
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containing 30 µg of protein, as determined by the BCA method (Pierce, Rockford, 
IL), were assayed. To determine the access of proinsulin to the retina, litters of 
P25 wt and rd10 mice were subcutaneously injected with 5 µg of hPi (in 100 µl of 
phosphate-buffered saline; Sigma P-4672, St Louis, MI; or kindly provided by Eli-
Lilly). Retinal extracts were prepared two hours later by dissecting and 
homogenizing one retina in 50 µl of the Tris-HCl buffer described above, and 
duplicates of 20 µl were assayed.  
Cell death progression 
Programmed cell death was determined by terminal deoxynucleotidyl 
transferase-mediated dUTP nick-end labeling (TUNEL). Mice of the indicated 
genotype and age were decapitated, their eyes enucleated and the retinas 
dissected out and flat-mounted onto nitrocellulose filter (Sartorius, Göttingen, 
Germany) photoreceptor layer side up. Retinas were then fixed in 4% (w/v) 
paraformaldehyde in 0.1 M phosphate buffer pH 7.4 at 4ºC overnight, and 
subsequently processed for TUNEL staining as described previously (Promega, 
Madison, WI; 27). After labeling, the retinas were mounted in Vectashield 
containing DAPI (Vector laboratories, Burlingame, CA) and analyzed on a TCS 
SP2 Laser-confocal microscope (Leica, Microsystems, Wetzlar, Germany). Serial 
optical sections were acquired with a 10X objective every 5 µm in depth around 
the optic nerve head. To ensure that TUNEL-positive nuclei were located in the 
outer nuclear layer (ONL) the depth of analysis was set according to ONL 
thickness, as determined in retinal sections. The number of total TUNEL-positive 
cells per mm2 was quantified in compiled projections from at least 4 retinas per 
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experimental group. The central retina area quantified represents approximately 
15% of the retinal surface. 
Histochemistry 
Animals from the different experimental groups were decapitated, their eyes 
enucleated, immediately embedded in Tissue-Tek (Sakura Finetek, Torrance, 
CA), and frozen in dry ice. Sections of 12 µm were cut with a cryostat (Leica CM 
1900, Leica Microsystems) and mounted on Poly-Lysine coated glass slides 
(Fisher Biotech, Pittsburgh, PA). Cryo-sections were then dried at room 
temperature, fixed for 15 min with 4% (w/v) paraformaldehyde in phosphate-
buffered saline and stained with Alexa 488-conjugated peanut agglutinin (1:500, 
Molecular Probes, Eugene, OR) or a rabbit anti-acrolein antibody (1:150; AbD 
Serotec, Oxford, UK) followed by Alexa 488-conjugated goat anti-rabbit Igs 
(1:200; Molecular Probes). After staining, sections were mounted in Vectashield 
(Vector Laboratories) containing DAPI to counterstain the nuclei. 
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Results  
Transgenic proinsulin expression preserves visual function in hPi/rd10 mice.  
The anti-apoptotic activity of proinsulin during retinal development 25 prompted us 
to investigate a possible effect of proinsulin in the photoreceptor apoptosis 
associated to retinal degeneration. We crossed two hPi transgenic mice lineages 
(L1 and L2) with the retinal degeneration model rd10 and analyzed the visual 
function of hPi/rd10 homozygous animals. ERG provided a comprehensive 
evaluation of visual function, both in scotopic (night, rod selective) and photopic 
(day-light, cone selective) conditions. While ERG waves could be recorded prior 
to degeneration in the rd10 mouse, as previously described 11, 12, 28, the ERG 
amplitudes diminished as retinal degeneration occurred and they became 
negligible by P30 (Fig. 1). By contrast, visual activity could still be measured at 
P30 in the two different hPi/rd10 mice lines (Fig. 1) and it was most prominent in 
the cones, whose degeneration is secondary to that of rods 29. Thus, transgenic 
expression of human proinsulin in muscle was able to attenuate the loss of vision 
in rd10 mice. 
The preservation of visual function in hPi/rd10 mice correlates with proinsulin 
levels.  
We assessed the correlation between hPi expression levels and the preservation 
of visual function, a particularly relevant issue when contemplating the 
therapeutic potential of any factor. As such, we evaluated visual function by 
recording ERGs from both homozygous and hemizygous hPi/rd10 animals of 
lineage 1. ERG responses were recorded at P30 in dark- and light-adapted 
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conditions to reflect rod- and cone-mediated vision, and standard ERG-wave 
amplitudes were determined. As a result, we identified significant differences in 
the averaged ERG amplitude values of bdim, OP, amax, bmax, bphot and flicker 
responses in each experimental group (Fig. 2). Indeed, each of these ERG 
parameters was higher in homozygous hPi/rd10 mice than in rd10 mice 
(p<0.001) and, notably, the mean amplitude values of flicker, bphot and OP were 
60%, 37% and 26% of the respective values from wt mice. Furthermore, OP, 
amax, and flicker values from hemizygous hPi/rd10 animals were also significantly 
higher than those from rd10 mice (p<0.01).  
Once we had established a correlation between visual function preservation and 
transgenic hPi gene dosage, we examined the correlation between hPi protein 
levels and visual function. The measured hPi concentrations in serum were 
below 15 pM, close to the inferior limit of the hPi ELISA kit used for their 
determination. Since the hPi transgene was under the control of the MLC-I 
muscle promoter, we determined the levels of hPi produced in muscle instead. 
Significant correlation between muscle hPi protein and several ERG parameters 
was found. Indeed, there was a hyperbolic correlation between hPi muscle 
content and the amplitudes of bmax, OP, bphot and flicker (Fig. 3). Therefore, a 
dose-response relationship between production of transgenic hPi in muscle and 
induced neuroprotection in the retina exists, which supports the potential 
therapeutic use of proinsulin. 
In addition, we evaluated the duration of the neuroprotective effect and functional 
preservation afforded by proinsulin, by comparing ERGs from wt, rd10 and 
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hPi/rd10 animals up to P55 (Fig. 4, and Supplementary Fig. 2). The scotopic and 
photopic b-waves (bmax and bphot) were partially preserved in hPi/rd10 mice even 
at P55, a period of time that doubled the period of vision in this model (Fig. 4). 
Remarkably, cone function was better preserved and long-lasting than rod 
function. Together, these experiments demonstrate that sustained low levels of 
systemic proinsulin actually delay visual loss in rd10 dystrophic animals.  
Systemic proinsulin reaches the retinal tissue and delays photoreceptor cell 
death.  
The effects of transgenic hPi reflected in the ERGs indicated that it acted directly 
or indirectly on retinal tissue, extending visual function. However, we were unable 
to detect hPi in retinal extracts from hPi/rd10 mice. Thus, to assess whether or 
not systemic proinsulin did indeed reach the retinal tissue, we subcutaneously 
injected a single dose of hPi (5 µg) and 2 hours later determined proinsulin 
content in serum and retinal extracts. In this manner we could detect proinsulin in 
the retina and, interestingly, retinal levels roughly correlated with proinsulinemia 
(Fig. 5). Thus, the incapacity to detect proinsulin in hPi/rd10 retinas probably 
reflects the very low amounts of proinsulin produced or accumulated by the 
animals, which nevertheless were sufficient to attenuate the loss of vision.  
The loss of visual function in rd10 mice is associated to massive loss of 
photoreceptors in the outer nuclear layer (ONL) 11, 12, 28. Since we observed 
attenuation of vision loss in transgenic hPi/rd10 animals, we investigated whether 
proinsulin expression was able to specifically interfere with photoreceptor 
apoptosis. Cell death, visualized by TUNEL staining of whole-mount retinas, was 
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delayed in hPi/rd10 when compared to rd10 mice (Fig. 6), an observation that 
paralleled the delay in the loss of visual function already described (Fig. 4). 
Therefore, systemic proinsulin was able to exert an anti-apoptotic effect on 
photoreceptors. 
Transgenic proinsulin preserves retinal structure and decreases oxidative 
damage.  
We further examined the histopathological aspects of the rd10 mouse retina in 
comparison with hPi/rd10. In agreement with our previous observations, 
transgenic hPi/rd10 animals displayed more photoreceptor rows than rd10 
animals at P32 (Fig. 7). This histological feature also correlated with transgene 
dosage, as described for the ERG (Fig. 2), as well as with proinsulinemia. Cone 
preservation was studied in more detail by staining the retina with the specific 
peanut agglutinin cone marker, which labels cone outer segments as well as 
synaptic terminals. A remarkable preservation of these cells was observed in 
hPi/rd10 retinas, sustaining the ERG cone responses described in Fig. 4. 
Increased lipid oxidation has been demonstrated in the retinas of rd1 and rd10 
mouse models 19, 30 and oxidative damage appears to trigger cell death in both, 
physiological and pathological conditions 31, 32. Thus, we determined whether 
proinsulin might interfere at this level of the neurodegenerative process. There 
was strong immunoreactivity for acrolein, a product of lipid oxidation, in the rd10 
mouse retina (Fig. 8), in accordance with previous observations of Komeima and 
collaborators 30. Interestingly, the immunoreactivity for acrolein was much weaker 
in hPi/rd10 transgenic animals than in rd10 at P32, suggesting that the 
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prevention of oxidative damage may be one of the primary effects of proinsulin 
(Fig. 8).  
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Discussion 
Together our results show that proinsulin preserves photoreceptor number and 
structure, as well as visual function in the degenerating rd10 mouse retina, 
fulfilling anti-apoptotic and anti-oxidant roles. Partial preservation of visual 
function in ERGs has been achieved by treatment with certain survival 
molecules, such as GDNF in the transgenic S334ter-4 rat 17, BDNF in the 
rhodopsin mutant mouse 18, and antioxidants in the rd1 mouse 19. Nevertheless, 
the preservation of ERG amplitudes reported in those studies is much lower than 
that observed here with proinsulin. Since different animal models and delivery 
methods have been employed, we can only claim at the present that proinsulin 
displays a promising neuroprotective effect. 
Another interesting difference of the approach adopted here is the effectiveness 
of systemic delivery. Most experimental treatments for RP involve direct retinal 
delivery by viral transfer 16, 17 retinal transgene expression 18, or by using 
intravitreal encapsulated cells 33. However, systemic administration of 
antioxidants has also been shown to provoke a modest neuroprotective effect 19, 
30. Although systemic delivery would perhaps not be the primary choice in retinal 
therapy, this aspect raises new questions about the biological availability of 
proinsulin and other members of this family in nervous tissue and their utility in 
neuroprotective therapies. Indeed, systemic IGF-I seems to be able to pass the 
blood-brain barrier and induce neuroprotection 34.  
We have found a hyperbolic correlation between the amount of proinsulin 
expressed in the muscle, where the transgene is transcriptionally active, and the 
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preservation of visual function parameters. This correlation is reminiscent of a 
receptor-mediated effect of proinsulin. Proinsulin has only weak affinity for the 
classic insulin-receptor and it has a poor metabolic potential (5-10 % of that of 
insulin; 35), which was reflected by the fact that all animals remained in the 
normal glycaemic and weight range (Supplementary Fig.1 and data not shown). 
An atypical, hybrid insulin/IGF-I receptor is present in the developing retina when 
proinsulin exerts its survival role with similar efficiency to insulin or IGF-I 27, 36. 
Proinsulin seems to block developmental cell death at various levels, including 
activation of PI3K/Akt and ERK pathways, stimulation of prosurvival chaperones, 
as well as interference with caspases and cathepsins 27, 37-40. This pleiotropic 
effect may underlie its neuroprotective action throughout blocking the multiple 
death pathways described in the rd muse models. To determine whether or not 
proinsulin survival pathways coincide under physiological and pathological 
conditions requires further studies. 
Cell death and visual loss still occur and eventually led to blindness in hPi/rd10 
mice. However, proinsulin provides an extended window of visual function, 
especially with respect to day-light vision, which may be a useful therapeutic 
approach to ameliorate the dramatic impact of RP in human patients. 
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FIGURE LEGENDS 
Figure 1.- ERG demonstrates the preservation of visual function in hPi/rd10 
mice. ERG’s were obtained from wt, rd10 and hPi/rd10 mice at P30. Examples 
from two different hPi/rd10 lineages (L1, L2) are shown. Rod and mixed 
responses were recorded under scotopic conditions to light flashes of -2.0 log 
cd·s·m-2 and 1.5 log cd·s·m-2, respectively. Cone-mediated responses were 
recorded to light flashes of 1.5 log cd·s·m-2 on a rod saturating background of 30 
cd·m-2. Standard ERG wave amplitudes are indicated in the wt mice panels for 
identification. The amplitudes of ERG recordings in the two hPi/rd10 animal 
lineages were higher than in rd10 animals. The same amplitude and time 
calibration are displayed for all recording traces. 
 
Figure 2.- Preservation of ERG wave amplitudes in hPi/rd10 mice correlates 
with hPi gene dosage. ERG wave amplitudes (bdim, OP, amax, bmax, bphot, flicker; 
see Fig. 1) were quantified in wt, rd10, hemizygous (hemi hPi/rd10) and 
homozygous (homo hPi/rd10) mice at P30. Each circle represents a single 
animal. A non-parametric Kruskall-Wallis analysis was performed on all groups 
and significant differences were found for all variables (p<0.001). Non-parametric 
Mann-Whitney analysis showed significant differences between wt animals and 
rd10, hemi hPi/rd10 and homo hPi/rd10 (a, p<0.001; a’, no differences wt vs. 
homo hPi/rd10). Differences between homozygous hPi/rd10 and rd10 were 
significant for all values (b, p<0.001). Differences between the hemizygous 
hPi/rd10 and rd10 were significant for values of amax, OP, and flicker (c, p<0.005). 
 18
Figure 3.- Preservation of ERG wave amplitudes in hPi/rd10 mice correlates 
with proinsulin levels in muscle. ERG wave amplitudes for bmax, OP, bphot and 
flicker are represented as a function of muscular proinsulin levels measured at 
P32. Each circle represents a single animal. A parametric Pearson test was 
performed and a significant hyperbolic correlation was found for bmax (r2=0.455, 
n=16, p<0.005), OP (r2=0.612, n=9, p<0.05), bphot (r2=0.504, n=16, p<0.005) and 
flicker (r2=0.498, n=13, p<0.01). 
 
Figure 4.- Visual function in hPi/rd10 mice is maintained longer than in rd10 
mice. ERG wave amplitudes were quantified in wt, rd10 and hPi/rd10 at the ages 
indicated and average values for bmax and bphot are shown (mean ± SEM, n= 4). 
Note that ERG waves in hPi/rd10 mice decay slower than in rd10 mice and that 
statistical significant differences were found (a, p<0.05; Kruskal-Wallis non-
parametric ANOVA; n.s., non-significant). 
 
Figure 5.- Systemic hPi is able to reach the retinal tissue. Litters of wt (closed 
circles) and rd10 mice (open circles) were subcutaneously injected at P25 with 5 
µg of hPi or vehicle (crosses). Proinsulin concentration was determined 2 hours 
later in serum and retinal extracts. Each symbol represents a single animal and 
proinsulin levels in the retinal tissue are represented as a function of 
proinsulinemia. Non-parametric Spearman Rho correlation with proinsulin 
injected mice (n=9) rendered rho=0.669 and p<0.05. 
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Figure 6.- Photoreceptor cell death is delayed in hPi/rd10 mice. Cell death 
was determined by TUNEL in whole-mount retinas of rd10 and hPi/rd10 mice at 
the ages indicated. Representative labeled retinas are shown at P25 (A and B). 
The total number of TUNEL-positive nuclei was quantified in confocal images of 
equivalent central retina fields, as those shown in A and B, from at least 4 retinas 
per experimental group and represented in (C). 
 
Figure 7.- Preservation of retinal structure in hPi/rd10 mice. Retinal sections 
from wt, rd10 and hPi/rd10 mice at P32 were stained with DAPI (blue) to reveal 
retinal cytoarchitecture and with Alexa488-peanut agglutinin (green) to visualize 
the state of cones. Preservation of photoreceptor rows (vertical bars), as well as 
preservation of cone outer segments (upper arrowhead) and synaptic terminals 
(lower arrowhead), correlate with proinsulin gene dosage, as well as with 
proinsulinemia (1.3 pM in the shown hemizygous; 2.4 pM in the shown 
heterozygous). Retinal layers are labeled: outer nuclear layer (ONL), inner 
nuclear layer (INL) and ganglion cell layer (GCL). Scale bar, 25 µm. 
 
Figure 8.- Reduction of lipid oxidation in hPi/rd10 mice. Retinal sections from 
wt, rd10 and hPi/rd10 mice at P32 were stained with DAPI (blue) to reveal retinal 
cytoarchitecture and with anti-acrolein antibody (green) to visualize oxidative 
damage. The increased lipid oxidation observed in rd10 retina is markedly 
reduced in hPi/rd10 animals. Retinal layers are labeled: outer nuclear layer 
(ONL), inner nuclear layer (INL) and ganglion cell layer (GCL). Scale bar, 25 µm. 
 20
 Supplemental material 
Figure S1.- Variations in glucose levels and weight in hPi transgenic mice. 
Paired groups of C57BL/6J and hPi transgenic mice were employed to determine 
the evolution of glucose levels and weight over time. The animals were weighed 
monthly over a 13-month period (Gram Precision GM-100, Gram Precision, 
L’Hospitalet de Llobregat, Spain) and after each weighing, the food was removed 
from the cage and 18 hours later a blood sample was taken to determine 
glycaemia (Roche Accu-Chek Sensor, Roche Diagnostic, Mannheim, Germany). 
Mean values (± SEM) are shown. 
 
Figure S2.- Visual function in hPi/rd10 mice is maintained for longer than in 
the 
rd10 animals. Mixed and cone responses were recorded in wt, rd10 and 
hPi/rd10 animals with respect to light flashes of 1.5 log cd·s·m-2 on postnatal day 
25, 35, 45 and 55 (indicated at the top of the recording traces). The complete 
disappearance of the ERG waves was observed in the rd10 control animals by 
p35 whereas in the hPi/rd10 animals, the ERG responses persisted even at P55. 
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